Prime Medicine, Inc.

NASDAQ:PRME

Biotechnology

Healthcare
$3.82 -1.11%

-$0.04 today

Market cap
$694.94M
Beta
2.31
P/E (TTM)
-2.8
EPS (TTM)
-$1.12
52W Low $1.77High $6.94

Volume 4.62M

Average 2.47M

PRME Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Prime Medicine, Inc.NASDAQ: PRME

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation dips below year-ago levels

Q1 FY2026 stock-based compensation of $4.64M fell 18.3% year over year, behind the +6.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 2.9% from the prior quarter. Over 3 fiscal years it compounded at +65.5% a year.

Context

  • Stock-based compensation amounted to 631.9% of revenue in FY2025, down 242.0 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -18.3% toward the trailing-twelve-month pace of +6.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.64M+2.9% QoQ
Last fiscal yearDec 2025
$29.27M+12.3% YoY
LTMMar 2026
$28.23M+6.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-18.3%——
1 year+12.3%——
3-year CAGR+65.5%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
29.27M USD
Year-over-year change
+12.3%
4-year CAGR
+102.3%

Stock-Based Compensation vs competitors

How PRME compares with its peers on the latest reported figures

  • PRME's LTM Mar 2026 stock-based compensation of $28.23M is the 3rd largest of the 7 companies compared; the peer median is $13.04M.
  • Its year-over-year change of +6.4% is the 2nd highest of 7, against a peer median of -20.8%.
  • Stock-based compensation amounts to 699.8% of revenue for PRME, versus a peer median of 99.6%.
PRME Competitors Peer median
Stock-Based Compensation for PRME and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$145.91M +2.8%+19.1%220.8%
CRSPCRISPR Therapeutics AGLTM Sep 2026$69.68M -8.8%-9.5%276.8%
PRMEPrime Medicine, Inc.LTM Mar 2026$28.23M +6.4%+65.5%699.8%
DSGNDesign Therapeutics, Inc.LTM Mar 2026$14.93M +11.2%+10.0%—
BEAMBeam Therapeutics Inc.LTM Jun 2026$12.73M -111.5%+3.8%8.2%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$11.16M -32.8%+2.7%99.6%
EDITEditas Medicine, Inc.LTM Mar 2026$9.12M -45.7%-30.1%23.6%
SCTXScribe Therapeutics Inc.—— ———
Peer median (excluding PRME) $13.04M-20.8%+3.2%99.6%

Competitors are the stored peer set for PRME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(165.37M)(121.82M)(198.13M)(195.88M)(201.14M)
Depreciation & Amortization568K2.22M4.65M6.13M5.38M
Deferred Income Tax(624K)(964K)(279K)00
Stock-Based Compensation1.75M6.46M13.91M26.07M29.27M
Change in Working Capital31.18M(35.4M)2.65M31.08M(5.34M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.19M2.46M9.14M(5.26M)996K
Other Working Capital29.99M(37.86M)(6.49M)36.33M(6.34M)
Other Non-Cash Items98.42M17.68M11.79M9.75M9.27M
Operating Cash Flow(34.08M)(131.83M)(165.41M)(122.87M)(162.56M)
Capital Expenditures(4.15M)(16.1M)(8.72M)(7.29M)(4.53M)
Acquisitions (Net)00000
Purchases of Investments(81.98M)(123.34M)(104.95M)(129.45M)(205.41M)
Sales of Investments13M93M132.56M204.2M101.18M
Other Investing Activities(496K)(665K)(170K)1M0
Investing Cash Flow(73.63M)(47.1M)18.71M68.46M(108.76M)
Debt Repayment00000
Common Stock Issued270.36M185.32M655K170.14M139.51M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.09M)(3.82M)025.74M12M
Financing Cash Flow269.28M181.49M655K195.88M151.51M
Effect of Forex Changes00000
Net Change in Cash161.57M2.57M(146.05M)141.47M(119.82M)
Free Cash Flow(38.23M)(147.92M)(174.14M)(130.16M)(167.1M)

Prime Medicine, Inc.

NASDAQ:PRME

Intrinsic Alpha fair value

Locked

Current Price

$3.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.